entinostat has been researched along with Dysmyelopoietic Syndromes in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Entinostat is a histone deacetylase inhibitor that has been combined with AZA with significant clinical activity in a previous phase I dose finding study." | 2.79 | Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. ( Czader, M; Erba, HP; Figueroa, ME; Gabrilove, J; Gore, SD; Greenberg, PL; Herman, J; Juckett, M; Ketterling, R; Litzow, M; Malick, L; Melnick, A; Paietta, E; Prebet, T; Smith, MR; Sun, Z; Tallman, MS, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Press, KR | 1 |
| Uy, N | 1 |
| Keefer, J | 1 |
| Gore, SD | 4 |
| Carraway, HE | 1 |
| Sakoian, S | 2 |
| Prebet, T | 3 |
| Sun, Z | 2 |
| Figueroa, ME | 1 |
| Ketterling, R | 1 |
| Melnick, A | 1 |
| Greenberg, PL | 1 |
| Herman, J | 2 |
| Juckett, M | 2 |
| Smith, MR | 2 |
| Malick, L | 2 |
| Paietta, E | 2 |
| Czader, M | 2 |
| Litzow, M | 2 |
| Gabrilove, J | 2 |
| Erba, HP | 2 |
| Tallman, MS | 2 |
| Ketterling, RP | 1 |
| Zeidan, A | 1 |
| Greenberg, P | 1 |
| Figueroa, M | 1 |
| Norsworthy, KJ | 1 |
| Cho, E | 1 |
| Arora, J | 1 |
| Kowalski, J | 1 |
| Tsai, HL | 1 |
| Warlick, E | 1 |
| Showel, M | 1 |
| Pratz, KW | 1 |
| Sutherland, LA | 1 |
| Ferguson, A | 1 |
| Greer, J | 1 |
| Espinoza-Delgado, I | 1 |
| Jones, RJ | 1 |
| Matsui, WH | 1 |
| Smith, BD | 1 |
| Gaymes, TJ | 1 |
| Shall, S | 1 |
| MacPherson, LJ | 1 |
| Twine, NA | 1 |
| Lea, NC | 1 |
| Farzaneh, F | 1 |
| Mufti, GJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Dose-Finding Trial of the Histone Deacetylase Inhibitor MS-275 (NSC 706995) in Combination With 5-Azacitidine (5AC, NSC 102816) in Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMMoL) and Acute Myeloid Leukemia (AML)[NCT00101179] | Phase 1 | 63 participants (Actual) | Interventional | 2004-11-03 | Completed | ||
| A Randomized Phase II Trial of Azacitidine With or Without the Histone Deacetylase Inhibitor Entinostat for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (Dysplastic Type), and Acute Myeloid Leukemia With Multilineage Dysplasi[NCT00313586] | Phase 2 | 197 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Clinical response is defined as a complete response (CR), partial response (PR) or trilineage response (TR) graded according to the following criteria:~World Health Organization classification of the acute leukemias and myelodysplastic syndrome (by Bennett)~Myelodysplastic syndromes standardized response criteria: further definition (by Cheson et al.)~Report of an international working group to standardize response criteria for myelodysplastic syndromes (by Cheson et al.)" (NCT00313586)
Timeframe: Assessed every 3 months if patient is < 2 years from study entry, every 6 months if patient is 2 - 5 years from study entry.
| Intervention | Proportion of patients (Number) |
|---|---|
| Arm A (Azacitidine; Non-treatment-induced Cohort) | 0.32 |
| Arm B (Azacitidine + Entinostat; Non-treatment-induced Cohort) | 0.27 |
| Arm A (Azacitidine; Treatment-induced Cohort) | 0.46 |
| Arm B (Azacitidine + Entinostat; Treatment-induced Cohort) | 0.17 |
3 trials available for entinostat and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2016 |
Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2016 |
Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2016 |
Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2016 |
Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Bexarotene; Female; Granulocyte-Macropha | 2016 |
2 other studies available for entinostat and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Clinical evaluation of combined azacitidine and entinostat on the induction of fetal hemoglobin in patients with acute myeloid leukemias and myelodysplastic syndromes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Clinical Trials, Phas | 2018 |
Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes.
Topics: Apoptosis; Azacitidine; Benzamides; Butyrates; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Surviva | 2009 |